Kintor Pharmaceutical Limited

Apr 21, 2024

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

Mar 14, 2024

Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature

Feb 22, 2021

Completion of Patients' Recruitment for Proxalutamide's COVID-19 Hospitalised Study

Feb 01, 2021

Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA

Jan 28, 2021

Clinical Trial of Proxalutamide's Trial of Hospitalized Covid-19 Patients Was Approved in Brazil

Jan 10, 2021

Kintor's Proxalutamide (GT0918) COVID-19 Clinical Trial Shows Positive Preliminary Results in Treatment of Female Patients

Dec 11, 2020

Kintor Proxalutamide's COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates

Dec 11, 2020

Kintor Pharmaceutical Announces Preliminary Results from the Proxalutamide's Clinical Trial

Dec 09, 2020

Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%

Oct 29, 2020

Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment